March 2013 | Oncology & Biotech News

April 11, 2013

Patients diagnosed with melanoma are typically affected psychologically. Researchers summarized health-related quality of life (HRQOL) during the 12-week ipilimumab induction period in previously treated patients diagnosed with advanced stage III or IV melanoma.

April 03, 2013

Analysis of the cost-effectiveness of ipilimumab compared with best supportive care in previously treated patients with advanced (unresectable or metastatic) melanoma.

April 02, 2013

The oncology we all learned over the past three decades will soon be a thing of the past, making way for therapy decisions based on what molecular switches should be turned on and off, and of equal importance, in what sequence.

March 29, 2013

The narrowing difference between operating cost and total medical revenue has eased, buying some time for practices to adjust their business models and perhaps survive.

March 28, 2013

Although it is now standard practice to utilize the second-generation TKIs dasatinib or nilotinib in patients whose CML has recurred while taking imatinib treatment, published support for the economic value of this approach is lacking.

March 27, 2013

Patients with advanced thyroid cancer who develop resistance to treatment with radioiodine may benefit from the experimental drug selumetinib.

March 25, 2013

Two novel, oral drugs that target the B-Cell receptor signal transduction pathway could significantly change the way chronic lymphocytic leukemia is treated.

March 22, 2013

15 years after treatment, patients have roughly equal odds of experiencing declines in functions, with no significant difference associated with their choice of either radical prostatectomy or external-beam radiation therapy.

March 20, 2013

A phase II study found that the novel small-molecule inhibitor selumetinib is well tolerated and achieved an objective response in patients with low-grade serous carcinoma of the ovary or peritoneum.